Beacon Pointe Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
Other funds holding BMRN
Beacon Pointe Advisors's BMRN Position: Q3 2026 in Review
Beacon Pointe Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2026: 3,433 shares worth $206K. The stake represents ﹤0.01% of the portfolio and ranks #1798 among its holdings. This is a return to the name: Beacon Pointe Advisors previously reported a position in BMRN as recently as Q2 2025.
Beacon Pointe Advisors first reported a position in BMRN in Q2 2021 and has held it in 18 quarters since. The position peaked at $1.85M in Q1 2023. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.
- Beacon Pointe Advisors held 3,433 shares of BioMarin Pharmaceuticals worth $206K as of Q3 2026.
- BioMarin Pharmaceuticals was a new Beacon Pointe Advisors position in Q3 2026.
- BioMarin Pharmaceuticals made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q3 2026, its #1798 holding.
- Beacon Pointe Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
- Beacon Pointe Advisors's BioMarin Pharmaceuticals position peaked at $1.85M in Q1 2023.
- 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.
Based on Beacon Pointe Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.